

Arrhythmogenic cardiomyopathy: what blood can reveal?



Ilaria Stadiotti, MSc,^{*} Giulio Pompilio, MD, PhD,^{*†} Angela Serena Maione, PhD,^{*} Chiara Assunta Pilato, MSc,^{*†} Yuri D'Alessandra, PhD,^{‡1} Elena Sommariva, PhD^{*1}

From the ^{*}Unit of Vascular Biology and Regenerative Medicine, Centro Cardiologico Monzino-IRCCS, Milan, Italy, [†]Department of Clinical Sciences and Community Health, Università degli Studi di Milano, Milan, Italy, and [‡]Unit of Immunology and Functional Genomics, Centro Cardiologico Monzino-IRCCS, Milan, Italy.

Blood, serum and plasma represent accessible sources of data about physiological and pathologic status. In arrhythmogenic cardiomyopathy (ACM), circulating nucleated cells are routinely used for detection of germinal genetic mutations. In addition, different biomarkers have been proposed for diagnostic purposes and for monitoring disease progression, including inflammatory cytokines, markers of myocardial dysfunction and damage, and microRNAs. This review summarizes the current information that can be retrieved from the blood of ACM patients and considers the future prospects. Improvements in current knowledge of circulating factors may provide noninvasive means to simplify and improve

the diagnosis, prognosis prediction, and management of ACM patients.

KEYWORDS Arrhythmogenic right ventricular cardiomyopathy; Biomarkers; Blood; Genetics; Heart failure; Inflammation; microRNA; Plasma; Serum

(Heart Rhythm 2019;16:470–477) © 2018 The Authors. Published by Elsevier Inc. on behalf of Heart Rhythm Society. This is an open access article under the CC BY-NC-ND license (<http://creativecommons.org/licenses/by-nc-nd/4.0/>).

Introduction

Blood is an easily accessible tissue, widely exploited in medicine to obtain clinical information at different levels. It serves as a window to monitor health or disease states because of its complex and “flexible” composition. Indeed, the whole set of molecules present in the blood originates from all body tissues, thus reflecting their fitness. In particular, several blood-based tests are routinely used to diagnose a wide number of pathologies, to understand their possible causes, to monitor the state of progression/remission and outcomes after treatment, and to help the choice of appropriate specific therapies as tools for theranostics.

Thus, research is continuously making remarkable efforts to improve the quantity and quality of information retrieved from this tissue. Blood complexity can be unraveled using different approaches, either omics- or hypothesis-driven, the latter usually originating from known molecular mechanisms involved in a specific disease.

Biomarkers are defined as disease indicators that can be measured accurately and reproducibly.¹ In particular, circulating biomarkers have the unquestionable advantage of being noninvasive and usually inexpensive. Despite these advantages, the number of clinical-grade biomarkers is limited, and the validation path of biomarkers possessing high sensitivity and/or specificity for a defined disease is challenging. This issue may be overcome by using a combination of different molecules.

In this review, we applied a structured literature search (Supplementary Methods and Supplemental Figure S1) to summarize the most up-to-date information retrievable from blood samples with regard to arrhythmogenic cardiomyopathy (ACM) patients (Figure 1). Because of their genetic basis, germinal mutations are routinely assessed in blood cells. However, much more information can be potentially unraveled. ACM inflammatory components can be studied through circulating lymphocytes–monocytes and cytokines, as well as possible systemic concomitant infective agents. Cardiac damage can be monitored by detecting released factors as well as circulating microRNAs (miRNAs). Sex prevalence is reflected in blood hormonal modulation. To date, no validated circulating biomarkers are available for ACM, and the few new candidates that have been proposed mainly provide indications about disease progression rather than onset. We speculate that advances beyond the

This work has been supported by Centro Cardiologico Monzino IRCCS, Ricerca Corrente from Italian Ministry of Health. The authors have no conflicts of interest to declare. ¹Dr Yuri D'Alessandra and Dr Elena Sommariva contributed equally to this work. **Address reprint requests and correspondence:** Dr Elena Sommariva, Centro Cardiologico Monzino-IRCCS, via Parea 4, 20138 Milan, Italy. E-mail address: esommariva@ccfm.it.




Figure 1 Graphic representation of a blood vessel and circulating cells and molecules that have been studied in blood, plasma, and serum from patients with arrhythmogenic cardiomyopathy. The main topics addressed in this review are highlighted in the boxes.

current knowledge will translate into future extensive exploitation of noninvasive blood tests in ACM.

ACM

ACM is a genetic and relatively rare cardiac disease characterized by ventricular fibrofatty substitution and arrhythmias.² In the majority of cases, involvement of the right ventricle (RV) is predominant, with a lesser representation of left dominant and biventricular forms.³

It mostly affects young men, particularly athletes, as intense physical exercise worsens the disease phenotype.⁴ Sustained myocardium workload provokes a training-induced heart remodeling that, despite being generally considered as physiological, can induce adverse alterations in predisposed subjects.

ACM onset usually occurs during adolescence and early adulthood.⁴ In many cases, nonspecific symptoms, such as syncope and palpitations, arise before the manifestation of overt myocardial dysfunction. Even in the context of well-preserved morphology, histology, and ventricular function, ACM patients may die of sudden cardiac death.⁵ As the disease progresses, the myocardial damage becomes evident, and structural anomalies such as regional wall-motion abnormalities, increased myocardial trabeculation, ventricular dilation, and dysfunction appear. At the histologic level, cardiomyocyte death, inflammation, and fibro-adipose substitution are observed.⁶

Currently there is no single gold standard diagnostic test for ACM. The diagnosis is based on a scoring system of “major” and “minor” criteria that include structural and electrocardiographic alterations, tissue characterization,

previous arrhythmic events, and family history. In selected cases, a genetic test is recommended.⁷

Genetics

Genetic tests are increasingly performed in the diagnostic process for inherited cardiovascular diseases. The opportunity to confirm diagnostic suspects or to identify at-risk relatives using blood samples is widely used in ACM, allowing etiologically based differential diagnosis if clinical presentation is not specific.⁸ Since 2000, molecular genetic analysis led to the discovery of many genes associated with ACM. To date, it is known that ACM has mostly a familial occurrence with an autosomal dominant inheritance.³ Recessive forms are also present, namely, Naxos and Carvajal syndromes, and are associated with a cutaneous phenotype.⁹

The most frequently mutated genes encode for desmosomal proteins, but mutations in nondesmosomal genes are also known.³ Desmosomes are intercellular junctions that provide cell-to-cell adhesion and influence intracellular transduction signals, through the Wnt pathway, which is impaired in ACM patients.¹⁰ These mutations lead to electrical and mechanical dysfunction of the myocardium. For a list of genes associated with ACM, see [Supplemental Table S1](#).

Genetic testing is initially recommended in 1 proband per family.¹¹ For each screened individual, cardiomyopathy gene panels could be used when clinical features overlap with other cardiac diseases or, when the phenotype is indisputable, a selected ACM-specific panel could be used.¹¹ When a causative mutation is identified, predictive genetic testing is applied to ascertain the presence of the disease in apparently

healthy relatives, in order to adopt preventive/follow-up strategies in individuals at risk.

Unfortunately, the genetic cause remains unknown in approximately 50% of probands with routine screening.¹² The success rate of genotyping could depend on several variables, such as cohort ethnicity, proband selection criteria, and the standards applied to understand the pathogenicity of the detected variants. Negative results could be due to the use of techniques that do not allow the detection of copy number variations.^{13,14} Moreover, phenotype misclassification could represent a considerable limit of this analysis.¹⁵ Furthermore, the presence of mutations in genes not yet associated with ACM could be an additional reason for low efficiency.¹²

Notably, compound or digenic heterozygosity is present in up to 18% of ACM patients, indicating that more than 1 pathogenic allele may be involved.^{16,17} Even if the value of genetics in risk stratification is poorly understood, multiple mutations¹⁸ and, possibly, mutations in the *PKP2* gene^{19,20} are predictors of more severe prognoses.

Because of this variability, even after genetic tests, ACM diagnosis and risk stratification are still challenging. Recently, different variants previously linked to ACM have been reclassified as variants of uncertain pathogenicity because they have been found also in large screenings of healthy subjects (see the ARVD/C Genetic Variants Database at <http://www.arvcdatabase.info> for indications on variant pathogenicity).^{21,22} The possible false-positive rate seems to be particularly high.²³ However, when a causal mutation is not detected, the complete exclusion of the disease is not possible.

Genetic and phenotypic overlap between ACM and other types of cardiomyopathy have been reported, particularly with dilated cardiomyopathy, Brugada syndrome, and hypertrophic cardiomyopathy (Supplemental Table S1).²⁴ In these cases, differential diagnosis is challenging even with the help of blood genetic tests.

The amount of implicated variables clearly defines how complex it is to obtain useful information on ACM genetics. Therefore, a great effort in the interpretation of the results is necessary to define their clinical significance, in addition to constant technical progresses. The advent of low-cost next-generation sequencing, the development of sophisticated analytics tools and models to test the pathogenicity of ACM mutations, and the increased knowledge about disease-associated genes represent significant steps forward in providing genetic diagnosis to patients.

Infections, inflammation, and immunity

An inflammatory milieu with patchy infiltrates in the RV has been observed in ACM hearts.²⁵ Thus, an inflammation theory was formulated to explain ACM etiology. In particular, it has been proposed that genetic mutations could induce immune alterations contributing to heart-specific inflammatory conditions.²⁶ The inflammatory process could provoke myocardial injury, followed by a genetically determined aberrant fibro-adipose repair. However, whether inflammation is a primary mechanism or a consequence of mutation-dependent

cardiomyocyte death is still unknown.²⁵ Indeed, inflammation related to necrosis and apoptosis has been reported, involving a feed-forward loop.²⁷

Most of the studies investigating ACM cardiac inflammation are based on invasive endomyocardial biopsy analysis to evaluate the presence of macrophages, neutrophils, and mast cells in the RV of ACM patients.²⁵ Also, the presence of cardiotropic viruses has been reported in the ACM myocardium, possibly contributing to the inflammatory environment.²⁸ In fact, a correlation between genetic predisposition and viral susceptibility has been proposed.²⁹ Because the use of cardiac biopsy is limited by its invasiveness, noninvasive techniques based on blood analysis to monitor cardiac inflammation are desirable. The detection of viruses and bacteria in the blood of ACM patients could reflect a cardiac infection. Chronic infections with *Bartonella henselae*, a bacterial agent associated with endocarditis detected in serum samples, have been proposed to be linked to ACM as a possible cause of nonfamilial ACM cases.³⁰

To date, circulating inflammatory mediators in ACM patients have been tested measuring different parameters. The plasmatic levels of the inflammatory marker C-reactive protein (CRP) are higher in the blood of patients with ACM than in those with idiopathic ventricular tachycardia (IVT), often in differential diagnosis. The association of an inflammatory status with the occurrence of arrhythmic events has been postulated because CRP levels significantly increase just after ventricular arrhythmia (VA) occurrence in ACM patients.³¹ However, because the CRP values of nonarrhythmic ACM patient subgroups have not been shown as well as those of the IVT cohort immediately after VA, CRP increase might be associated with VA and not with ACM. In addition, higher levels of circulating proinflammatory cytokines have been found in ACM patients compared to healthy controls.^{32,33} Although the inflammatory status of the heart has been associated with disease severity,²⁵ no studies have correlated circulating cytokine levels to myocardial damage degree.

Myocarditis is often in the differential diagnosis with ACM. However, it has been postulated that myocarditis is a superimposed phenomenon during the natural history of ACM, being associated with an active progression phase.³⁴ To date, no study has addressed the role of circulating factors in the differential diagnosis between these 2 diseases.

Recently, an autoimmune etiology has been proposed³⁵; however, the presence of autoantibodies against desmosomal components in ACM plasma needs to be confirmed in larger cohorts.

Thus, to date, a complete characterization of circulating inflammatory/immune response in ACM is still lacking. A large analysis of inflammatory cell mediators, antibodies, and cytokines may help define an ACM-specific inflammatory cascade³⁶ and improve diagnostic and prognostic processes along with pathogenic mechanisms.

Circulating biomarkers of damage

Heart failure (HF) in ACM is a severe consequence of an advanced cardiac remodeling process. Thus, the exploitation

of different HF biomarkers are proposed for the characterization of ACM late phases. Circulating brain natriuretic peptide (BNP) is routinely used to evaluate the presence and progression of HF and has been shown to be a useful indicator of RV dysfunction in ACM patients due to the reported negative correlation with RV ejection fraction.³⁷ Of note, BNP is higher in the plasma of ACM vs IVT patients, which aids differential diagnosis. Accordingly, immunohistochemistry performed on endomyocardial biopsies showed no detectable BNP in the RV of IVT patients, whereas positive results were obtained in ACM patients.³⁷ Similar experiments using the N-terminal fragment of BNP, NT-proBNP, showed its association with RV dysfunction and volumes in ACM.³⁸ This observation has been confirmed in other studies.³⁹ The major limitation of the use of BNP and NT-proBNP in association with ACM is its low specificity due to the well-known association with a large number of HF-related cardiac conditions.

In 2009, the chaperone heat shock protein 70 (HSP70) was found to be differentially expressed in failing hearts of ACM patients in comparison to nonfailing hearts, with similar results at the systemic level.⁴⁰ Based on *in vitro* results, circulating HSP70 was proposed to originate from damaged myocardial cells. Other evidences associated HSP70 with inflammation and apoptosis.⁴¹ Similarly to BNP, HSP70 usage is limited by its lack of ACM specificity because it is elevated in patients with dilated cardiomyopathy and ischemic cardiomyopathy.

Likewise, cardiac troponin I (cTnI), a structural protein released into circulation after cardiomyocyte death and a well-established marker of cardiac muscle injury, has been proposed to be associated with ACM.⁴² The first evidence was observed in ACM boxer dogs, in which a correlation between cTnI levels and premature ventricular contractions was demonstrated.⁴³ This was confirmed in humans, highlighting a correlation of cTnI with major arrhythmic events.³⁹ However, its use in ACM is questionable because troponin increase also has been observed in athletes with ischemia⁴⁴ or myocarditis⁴⁵ and in agonist athletes after strenuous physical activity.⁴⁶

In 2012, Hong et al⁴⁷ proposed bridging integrator 1 (BIN1) as a marker of cardiac functional status and for predicting the risk of development of ventricular arrhythmias in ACM patients with HF. Decreased levels of BIN1 (a regulator of calcium transients and contractility) were found in the blood of ACM patients with HF, suggesting its possible use as biomarker.⁴⁷ However, this hypothesis is limited by the observation that BIN1 levels in ACM patients without HF are comparable to those found in healthy controls, thus limiting its usefulness to advanced stages of the disease.⁴⁸

In 2017, Broch et al⁴⁹ analyzed the plasmatic levels of interleukin-33 receptor ST2, which was previously associated with cardiac remodeling and fibrosis.⁵⁰ They observed a correlation between circulating ST2, right and left ventricular function, and arrhythmia occurrence in ACM. They proposed ST2 as a possible biomarker of disease severity upon validation in prospective studies.

Another described marker of fibrotic substitution in ACM patients, galectin-3 (GAL-3), was found increased in ACM

plasmatic samples compared to controls. Strikingly, GAL-3 differential levels between patients with and those without arrhythmic events during the follow-up period were assessed, indicating a GAL-3 predictive value for VA in these patients.⁵¹

Because ST2 and GAL-3, beside fibrosis, were also associated with inflammation,⁵² future investigations should evaluate the correlation with the extent of fibrosis in ACM patients.

Thus, the introduction of the described biomarkers in the clinical scenario for diagnostic, prognostic, or severity evaluation purposes still needs refinements. Many of these circulating biomarkers are used for other cardiac diseases in which HF is a common underlying hallmark. As mentioned, however, ACM patients only show HF signs in the later stage of the disease, so the impact of HF-related biomarker is limited. Similarly, the arrhythmic phenotype of ACM has been associated with other circulating biomarkers, but the lack of specificity for ACM does not allow the use of a single biomarker for diagnosis and patient management.

Sex hormones

Because males are more frequently affected by ACM than females, sex hormones and their correlation to disease severity have been tested.³⁹ A general increase of testosterone serum levels was found in male and female ACM patients with major adverse cardiac events compared to those without. This is in line with previous results that showed the role of testosterone in the stimulation of arrhythmias.⁵³ Accordingly, in female patients with arrhythmic events, estradiol levels were lower, indicating a possible cardioprotective role of this sex hormone.⁵⁴

A direct role for sex hormones in ACM cellular pathogenic changes has been proposed using induced pluripotent stem cell-derived cardiomyocytes. In this model, testosterone administration increased apoptosis and lipogenesis whereas estradiol ameliorated these phenotypes,³⁹ possibly through already described mechanisms.⁵⁵ However, hormones are not stable, and several factors could affect their levels. Thus, the clinical use of sex hormone dosage/therapy in correlation with ACM severity remains challenging.

miRNAs

miRNAs are short (22–24 nucleotides) noncoding RNAs involved in several biological and pathologic processes. As a consequence of their regulatory role, expression levels of miRNAs are prone to frequent variations in response to several stimuli, including pathologies such as cancer, cardiovascular diseases, inflammation, and neurological disorders.^{56,57}

In the last few years, miRNAs have attracted the attention of researchers and clinicians because of their potential utility as biomarkers in relation to their presence in almost all biological fluids, including plasma and serum.⁵⁸ Notably, with regard to cardiac diseases, several reports have described the diagnostic potential of circulating miRNAs.^{59–61} Few studies have evaluated circulating miRNAs in ACM. We were the first, in 2017, to find a correlation between ACM

Table 1 Summary of circulating factors studied in ACM

Circulating factors	Regulation in ACM	In clinical use	Possible clinical application in ACM	Proposed pathophysiology	Reference
Genetics					
DNA from blood cells		Yes	• Diagnosis • Differential diagnosis	Causative genes	Table S1
Inflammation					
Viruses and bacteria	↑	Yes	• Severity (HF and arrhythmias)	Cardiac infection enhancing cardiac remodeling	30
Inflammatory cytokines	↑	Yes	• Severity	Cause and/or consequence of cardiac injury	32, 33
C-reactive protein	↑	Yes	• Differential diagnosis with IVT or myocarditis	Consequence of cardiac injury	31
Biomarkers of damage					
Brain natriuretic peptide (BNP)	↑	Yes	• Severity (HF) • Prognosis (arrhythmias) • Differential diagnosis with IVT	Consequence of cardiac injury Response to stretch	37, 39
Heat shock protein 70 (HSP70)	↑	No	• Severity (HF)	Consequence of cardiac injury Associated to inflammation and apoptosis	40
Cardiac troponin I (cTnI)	↑	Yes	• Severity (HF) • Prognosis (arrhythmias)	Consequence of cardiac injury and cardiomyocyte death	39
Bridging integrator 1 (BIN1)	↑	No	• Prognosis (arrhythmias)	Consequence of cardiac injury	47
ST2	↑	Yes	• Severity (HF and arrhythmias)	Associated to inflammation and cardiac fibrotic remodeling	49
Galectin-3	↑	Yes	• Prognosis (arrhythmias) • Severity (HF)	Associated to inflammation and cardiac fibrotic remodeling	51
Hormones					
Sex hormones	↓ ↑	Yes	• Prognosis (arrhythmias) • Severity (HF)	Direct effect on cardiomyocyte lipogenesis and apoptosis	39
MicroRNAs					
miR-320a	↓	No	• Differential diagnosis with IVT	Targets Wnt pathway, regulates apoptosis and adipogenesis	62
miR-144-3p, 145-5p, 185-5p, and 494	↑	No	• Differential diagnosis with IVT • Prognosis (arrhythmias)	Associated to apoptosis	65

For each circulating factor, regulation in arrhythmogenic cardiomyopathy (ACM), current general clinical use, possible application of each factor in ACM, and proposed pathophysiology are indicated.

HF = heart failure; IVT = idiopathic ventricular tachycardia.

and low plasma levels of miR-320a.⁶² These levels were unaffected by physical activity, a recognized ACM-precipitating factor, suggesting that its modulation in ACM is independent of training-induced heart remodeling. Furthermore, miR-320a was valuable in distinguishing ACM subjects from IVT patients. Interestingly, miR-320a seemed to have mechanistic implications in ACM pathogenesis. It

was increased during adipogenic differentiation of human mesenchymal bone marrow cells⁶³ and in regulating the Wnt pathway in human colon cancer cells.⁶⁴ Thus, it can be expected that deregulated miR-320a expression is related to cardiac cell apoptosis and adipogenesis. The diagnostic value of miR-320a needs to be validated in larger cohorts of ACM patients.

A similar study on circulating miRNAs in ACM patients with VA was published.⁶⁵ Yamada et al⁶⁵ observed higher expressions of miR-144-3p, 145-5p, 185-5p, and 494 in ACM patients with VA compared to healthy controls, IVT patients, and subjects with suspected ACM. Among them, miR-494 seemed to have a central prognostic value because it was linked to recurrent VA after ablation. Moreover, based on *in vitro* results, a possible correlation between the high expression of miR-494 and the apoptotic process occurring in ACM hearts was proposed despite the role of miR-494 in apoptosis being unclear due to its dual modulation of both anti- and proapoptotic genes.⁶⁶

Although the interest in circulating miRNAs as disease biomarkers has increased steadily during the last few years, several limitations still hamper their introduction in daily clinical practice. One of the most important issues is the difficulty in standardizing detection and quantification methods.⁵⁸ Nevertheless, their undisputable potential and the higher sensitivity and specificity in comparison to other biomarker candidates may represent an advantage that can overcome technical issues, thus ensuring their implementation in the clinical setting.

Conclusion

In this review, we summarized several aspects of ACM in relation to blood-based analyses, including genetics, inflammation, and a variety of novel potential circulating biomarkers associated with different ACM features (Figure 1 and Table 1).

Although many of the tests are routinely included in the clinical practice of various diseases, many limitations are still present and need to be addressed before they can be exploited in the ACM field. For example, ACM prognostic specificity and yield in differential diagnosis, both against other arrhythmic or HF diseases and against athletes' hearts, must be delineated. Many studies have reported that intense training induces the release into the circulation of most of the proposed biomarkers.^{46,67–71}

The future identification of new ACM-specific biomarkers, either alone or in combination, may overcome the current limitations. In order to achieve this goal, several validation steps for suitable candidates in wide patient cohorts are mandatory to define disease thresholds and admission to clinical practice in order to help patient diagnosis and stratification.

Notably, to date no circulating biomarkers have been proposed in relation to some crucial ACM features, including fibro-adipose substitution. Speculatively, ACM-specific cardiac remodeling may be the source of circulating “debris” that could be exploited as a diagnostic marker. Alternatively, the identification of clinically relevant biomarkers using hypothesis-generating “omics” approaches could provide new hints about unexplored ACM mechanisms and therapeutic targets.

The current knowledge of circulating factors in ACM blood is limited, and clinical application is restricted to genetics and a few HF biomarkers (Table 1). Further research will improve the use of noninvasive blood tests in patients with ACM.

Acknowledgments

A special thanks to Drs Perrucci and Zoofito for technical assistance with the figure, and to Dr Gowran for manuscript revision.

Appendix Supplementary data

Supplementary data associated with this article can be found in the online version at <https://doi.org/10.1016/j.hrthm.2018.09.023>.

References

1. Strimbu K, Tavel JA. What are biomarkers? *Curr Opin HIV AIDS* 2010; 5:463–466.
2. Stadiotti I, Catto V, Casella M, Tondo C, Pompilio G, Sommariva E. Arrhythmogenic cardiomyopathy: the guilty party in adipogenesis. *J Cardiovasc Transl Res* 2017;10:446–454.
3. McNally E, MacLeod H, Dellefave-Castillo L. Arrhythmogenic right ventricular cardiomyopathy. April 18, 2005. Updated May 25, 2017. In: Adam MP, Ardinger HH, Pagon RA, et al., eds. *GeneReviews*. Seattle, WA: University of Washington, Seattle; 1993–2018. 1993–2018. Available from: <https://www.ncbi.nlm.nih.gov/books/NBK1131/>.
4. Castanos Gutierrez SL, Kamel IR, Zimmerman SL. Current concepts on diagnosis and prognosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia. *J Thorac Imaging* 2016;31:324–335.
5. Sommariva E, Stadiotti I, Perrucci GL, Tondo C, Pompilio G. Cell models of arrhythmogenic cardiomyopathy: advances and opportunities. *Dis Model Mech* 2017;10:823–835.
6. Saguner AM, Bruckhorst C, Duru F. Arrhythmogenic ventricular cardiomyopathy: a paradigm shift from right to biventricular disease. *World J Cardiol* 2014;6:154–174.
7. Marcus FI, McKenna WJ, Sherrill D, et al. Diagnosis of arrhythmogenic right ventricular cardiomyopathy/dysplasia: proposed modification of the task force criteria. *Circulation* 2010;121:1533–1541.
8. Marcus FI, Edson S, Towbin JA. Genetics of arrhythmogenic right ventricular cardiomyopathy: a practical guide for physicians. *J Am Coll Cardiol* 2013; 61:1945–1948.
9. Protonotarios N, Tsatsopoulou A. Naxos disease and Carvajal syndrome: cardiocutaneous disorders that highlight the pathogenesis and broaden the spectrum of arrhythmogenic right ventricular cardiomyopathy. *Cardiovasc Pathol* 2004; 13:185–194.
10. Garcia-Gras E, Lombardi R, Giocondo MJ, Willerson JT, Schneider MD, Khoury DS, Marian AJ. Suppression of canonical Wnt/beta-catenin signaling by nuclear plakoglobin recapitulates phenotype of arrhythmogenic right ventricular cardiomyopathy. *J Clin Invest* 2006;116:2012–2021.
11. Cirino AL, Harris S, Lakdawala NK, et al. Role of genetic testing in inherited cardiovascular disease: a review. *JAMA Cardiol* 2017;2:1153–1160.
12. Fedida J, Fressart V, Charron P, Surget E, Hery T, Richard P, Donal E, Keren B, Duthoit G, Hidden-Lucet F, Villard E, Gandjbakhch E. Contribution of exome sequencing for genetic diagnostic in arrhythmogenic right ventricular cardiomyopathy/dysplasia. *PLoS One* 2017;12:e0181840.
13. Pilichou K, Lazzarini E, Rigato I, et al. Large genomic rearrangements of desmosomal genes in Italian arrhythmogenic cardiomyopathy patients. *Circ Arrhythm Electrophysiol* 2017;10:e005324.
14. Roberts J, Herkert J, Rutberg J, Nikkel S, Wiesfeld A, Dooijes D, Gow R, van Tintelen J, Gollob M. Detection of genomic deletions of PKP2 in arrhythmogenic right ventricular cardiomyopathy. *Clin Genet* 2013;83:452–456.
15. Ott P, Marcus FI, Sobonya RE, Morady F, Knight BP, Fuenzalida CE. Cardiac sarcoidosis masquerading as right ventricular dysplasia. *Pacing Clin Electrophysiol* 2003;26:1498–1503.
16. Xu T, Yang Z, Vatta M, et al. Compound and digenic heterozygosity contributes to arrhythmogenic right ventricular cardiomyopathy. *J Am Coll Cardiol* 2010; 55:587–597.
17. König E, Volpato CB, Motta BM, et al. Exploring digenic inheritance in arrhythmogenic cardiomyopathy. *BMC Med Genet* 2017;18:145.
18. Rigato I, Bauce B, Rampazzo A, et al. Compound and digenic heterozygosity predicts lifetime arrhythmic outcome and sudden cardiac death in desmosomal gene-related arrhythmogenic right ventricular cardiomyopathy. *Circ Cardiovasc Genet* 2013;6:533–542.

19. Sommariva E, Brambilla S, Carbuicchio C, et al. Cardiac mesenchymal stromal cells are a source of adipocytes in arrhythmogenic cardiomyopathy. *Eur Heart J* 2016;37:1835–1846.
20. Bao J, Wang J, Yao Y, Wang Y, Fan X, Sun K, He DS, Marcus FI, Zhang S, Hui R, Song L. Correlation of ventricular arrhythmias with genotype in arrhythmogenic right ventricular cardiomyopathy. *Circ Cardiovasc Genet* 2013;6:552–556.
21. Hall CL, Sutanto H, Dalageorgou C, McKenna WJ, Syrris P, Futema M. Frequency of genetic variants associated with arrhythmogenic right ventricular cardiomyopathy in the genome aggregation database. *Eur J Hum Genet* 2018;26:1312–1318.
22. van der Zwaag PA, Jongbloed JD, van den Berg MP, van der Smagt JJ, Jongbloed R, Bikker H, Hofstra RM, van Tintelen JP. A genetic variants database for arrhythmogenic right ventricular dysplasia/cardiomyopathy. *Hum Mutat* 2009;30:1278–1283.
23. Kapplinger JD, Landstrom AP, Salisbury BA, et al. Distinguishing arrhythmogenic right ventricular cardiomyopathy/dysplasia-associated mutations from background genetic noise. *J Am Coll Cardiol* 2011;57:2317–2327.
24. Murray B, Hoorntje ET, Te Riele A, et al. Identification of sarcomeric variants in probands with a clinical diagnosis of arrhythmogenic right ventricular cardiomyopathy (ARVC). *J Cardiovasc Electrophysiol* 2018;29:1004–1009.
25. Campuzano O, Alcalde M, Iglesias A, Barahona-Dussault C, Sarquella-Brugada G, Benito B, Arzamendi D, Flores J, Leung TK, Talajic M, Oliva A, Brugada R. Arrhythmogenic right ventricular cardiomyopathy: severe structural alterations are associated with inflammation. *J Clin Pathol* 2012;65:1077–1083.
26. Cooper LT Jr. Myocarditis. *N Engl J Med* 2009;360:1526–1538.
27. Haanen C, Vermes I. Apoptosis and inflammation. *Mediators Inflamm* 1995;4:5–15.
28. Bowles NE, Ni J, Marcus F, Towbin JA. The detection of cardiotropic viruses in the myocardium of patients with arrhythmogenic right ventricular dysplasia/cardiomyopathy. *J Am Coll Cardiol* 2002;39:892–895.
29. Calabrese F, Basso C, Carturan E, Valente M, Thiene G. Arrhythmogenic right ventricular cardiomyopathy/dysplasia: is there a role for viruses? *Cardiovasc Pathol* 2006;15:11–17.
30. H Fischer A, van der Loo B, M Shar G, Zbinden R, Duru F, Brunckhorst C, Rousson V, Delacretaz YE, Stuber T, Oechslin EN, Follath F, Jenni R. Serological evidence for the association of Bartonella henselae infection with arrhythmogenic right ventricular cardiomyopathy. *Clin Cardiol* 2008;31:469–471.
31. Bonny A, Lellouche N, Ditah I, Hidden-Lucet F, Yitemben MT, Granger B, Larrazet F, Frank R, Fontaine G. C-reactive protein in arrhythmogenic right ventricular dysplasia/cardiomyopathy and relationship with ventricular tachycardia. *Cardiol Res Pract* 2010;2010:919783.
32. Campian ME, Verberne HJ, Hardziyenka M, de Groot EA, van Moerkerken AF, van Eck-Smit BL, Tan HL. Assessment of inflammation in patients with arrhythmogenic right ventricular cardiomyopathy/dysplasia. *Eur J Nucl Med Mol Imaging* 2010;37:2079–2085.
33. Asimaki A, Tandri H, Duffy ER, et al. Altered desmosomal proteins in granulomatous myocarditis and potential pathogenic links to arrhythmogenic right ventricular cardiomyopathy. *Circ Arrhythm Electrophysiol* 2011;4:743–752.
34. Pilichou K, Thiene G, Baucé B, Rigato I, Lazzarini E, Migliore F, Perazzolo Marra M, Rizzo S, Zorzi A, Daliento L, Corrado D, Basso C. Arrhythmogenic cardiomyopathy. *Orphanet J Rare Dis* 2016;11:33.
35. Chatterjee D, Fatah M, Adkiss D, Spears DA, Koopmann T, Mittal K, Brunckhorst C, Duri F, Saguner A, Hamilton R. A novel serum biomarker identifying arrhythmogenic right ventricular cardiomyopathy (ARVC). *Eur Heart J* 2017;38 <https://doi.org/10.1093/eurheartj/ehx494.2889>.
36. Ciulla MM, De Marco F, Montelatici E, Lazzari L, Perrucci GL, Magrini F. Assessing cytokines' talking patterns following experimental myocardial damage by applying Shannon's information theory. *J Theor Biol* 2014;343:25–31.
37. Matsuo K, Nishikimi T, Yutani C, Kurita T, Shimizu W, Taguchi A, Suyama K, Aihara N, Kamakura S, Kangawa K, Takamiya M, Shimomura K. Diagnostic value of plasma levels of brain natriuretic peptide in arrhythmogenic right ventricular dysplasia. *Circulation* 1998;98:2433–2440.
38. Cheng H, Lu M, Hou C, Chen X, Wang J, Yin G, Chu J, Zhang S, Prasad SK, Pu J, Zhao S. Relation between N-terminal pro-brain natriuretic peptide and cardiac remodeling and function assessed by cardiovascular magnetic resonance imaging in patients with arrhythmogenic right ventricular cardiomyopathy. *Am J Cardiol* 2015;115:341–347.
39. Akdis D, Saguner AM, Shah K, Wei C, Medeiros-Domingo A, von Eckardstein A, Luscher TF, Brunckhorst C, Chen HSV, Duru F. Sex hormones affect outcome in arrhythmogenic right ventricular cardiomyopathy/dysplasia: from a stem cell derived cardiomyocyte-based model to clinical biomarkers of disease outcome. *Eur Heart J* 2017;38:1498–1508.
40. Wei YJ, Huang YX, Shen Y, Cui CJ, Zhang XL, Zhang H, Hu SS. Proteomic analysis reveals significant elevation of heat shock protein 70 in patients with chronic heart failure due to arrhythmogenic right ventricular cardiomyopathy. *Mol Cell Biochem* 2009;332:103–111.
41. Snoeckx LH, Cornelussen RN, Van Nieuwenhoven FA, Reneman RS, Van Der Vusse GJ. Heat shock proteins and cardiovascular pathophysiology. *Physiol Rev* 2001;81:1461–1497.
42. Adams JE 3rd, Bodor GS, Davila-Roman VG, Delmez JA, Apple FS, Ladenson JH, Jaffe AS. Cardiac troponin I. A marker with high specificity for cardiac injury. *Circulation* 1993;88:101–106.
43. Baumwart RD, Orvalho J, Meurs KM. Evaluation of serum cardiac troponin I concentration in Boxers with arrhythmogenic right ventricular cardiomyopathy. *Am J Vet Res* 2007;68:524–528.
44. Mahajan N, Mehta Y, Rose M, Shani J, Lichstein E. Elevated troponin level is not synonymous with myocardial infarction. *Int J Cardiol* 2006;111:442–449.
45. Smith SC, Ladenson JH, Mason JW, Jaffe AS. Elevations of cardiac troponin I associated with myocarditis. Experimental and clinical correlates. *Circulation* 1997;95:163–168.
46. Saenz AJ, Lee-Lewandrowski E, Wood MJ, Neilan TG, Siegel AJ, Januzzi JL, Lewandrowski KB. Measurement of a plasma stroke biomarker panel and cardiac troponin T in marathon runners before and after the 2005 Boston marathon. *Am J Clin Pathol* 2006;126:185–189.
47. Hong TT, Cogswell R, James CA, et al. Plasma BIN1 correlates with heart failure and predicts arrhythmia in patients with arrhythmogenic right ventricular cardiomyopathy. *Heart Rhythm* 2012;9:961–967.
48. Asimaki A. BIN1: a new biomarker to track ARVC? *Heart Rhythm* 9:968–969.
49. Broch K, Leren IS, Saberniak J, Ueland T, Edvardsen T, Gullestad L, Haugaa KH. Soluble ST2 is associated with disease severity in arrhythmogenic right ventricular cardiomyopathy. *Biomarkers* 2017;22:367–371.
50. Weinberg EO, Shimp M, De Keulenaer GW, MacGillivray C, Tominaga S, Solomon SD, Rouleau JL, Lee RT. Expression and regulation of ST2, an interleukin-1 receptor family member, in cardiomyocytes and myocardial infarction. *Circulation* 2002;106:2961–2966.
51. Oz F, Onur I, Elitok A, Ademoglu E, Altun I, Bilge AK, Adalet K. Galectin-3 correlates with arrhythmogenic right ventricular cardiomyopathy and predicts the risk of ventricular arrhythmias in patients with implantable defibrillators. *Acta Cardiol* 2017;72:453–459.
52. Milovanovic M, Volarevic V, Radosavljevic G, Jovanovic I, Pejnovic N, Arsenijevic N, Lukic ML. IL-33/ST2 axis in inflammation and immunopathology. *Immunol Res* 2012;52:89–99.
53. Ayaz O, Howlett SE. Testosterone modulates cardiac contraction and calcium homeostasis: cellular and molecular mechanisms. *Biol Sex Differ* 2015;6:9.
54. Giordano S, Hage FG, Xing D, Chen YF, Allon S, Chen C, Oparil S. Estrogen and Cardiovascular Disease: Is Timing Everything? *Am J Med Sci* 2015;350:27–35.
55. Mauvais-Jarvis F. Estrogen and androgen receptors: regulators of fuel homeostasis and emerging targets for diabetes and obesity. *Trends Endocrinol Metab* 2011;22:24–33.
56. Krol J, Loedige I, Filipowicz W. The widespread regulation of microRNA biogenesis, function and decay. *Nat Rev Genet* 2010;11:597–610.
57. Ruggeri C, Goffredi S, Achilli F, Colombo GI, D'Alessandra Y. Role of microRNAs in doxorubicin-induced cardiotoxicity: an overview of preclinical models and cancer patients. *Heart Fail Rev* 2018;23:109–122.
58. Ghai V, Wang K. Recent progress toward the use of circulating microRNAs as clinical biomarkers. *Arch Toxicol* 2016;90:2959–2976.
59. D'Alessandra Y, Carena MC, Spazzafumo L, et al. Diagnostic potential of plasmatic MicroRNA signatures in stable and unstable angina. *PLoS One* 2013;8:e80345.
60. Wong LL, Armugam A, Sepramaniam S, et al. Circulating microRNAs in heart failure with reduced and preserved left ventricular ejection fraction. *Eur J Heart Fail* 2015;17:393–404.
61. McManus DD, Tanriverdi K, Lin H, et al. Plasma microRNAs are associated with atrial fibrillation and change after catheter ablation (the miRhythm study). *Heart Rhythm* 2015;12:3–10.
62. Sommariva E, D'Alessandra Y, Farina FM, et al. MiR-320a as a potential novel circulating biomarker of arrhythmogenic cardiomyopathy. *Sci Rep* 2017;7:4802.
63. Hamam D, Ali D, Vishnubalaji R, Hamam R, Al-Nbaheen M, Chen L, Kassem M, Aldahmash A, Alajez NM. microRNA-320/RUNX2 axis regulates adipocytic differentiation of human mesenchymal (skeletal) stem cells. *Cell Death Dis* 2014;5:e1499.
64. Sun JY, Huang Y, Li JP, Zhang X, Wang L, Meng YL, Yan B, Bian YQ, Zhao J, Wang WZ, Yang AG, Zhang R. MicroRNA-320a suppresses human colon cancer cell proliferation by directly targeting beta-catenin. *Biochem Biophys Res Commun* 2012;420:787–792.

65. Yamada S, Hsiao YW, Chang SL, et al. Circulating microRNAs in arrhythmic right ventricular cardiomyopathy with ventricular arrhythmia. *Europace* 2018;20:f37–f45.
66. Wang X, Zhang X, Ren XP, Chen J, Liu H, Yang J, Medvedovic M, Hu Z, Fan GC. MicroRNA-494 targeting both proapoptotic and antiapoptotic proteins protects against ischemia/reperfusion-induced cardiac injury. *Circulation* 2010;122:1308–1318.
67. Aengevaeren VL, Hopman MTE, Thijssen DHJ, van Kimmenade RR, de Boer MJ, Eijssvogels TMH. Endurance exercise-induced changes in BNP concentrations in cardiovascular patients versus healthy controls. *Int J Cardiol* 2017;227:430–435.
68. Hattasch R, Spethmann S, de Boer RA, et al. Galectin-3 increase in endurance athletes. *Eur J Prev Cardiol* 2014;21:1192–1199.
69. Banfi G, Dolci A, Verna R, Corsi MM. Exercise raises serum heat-shock protein 70 (Hsp70) levels. *Clin Chem Lab Med* 2004;42:1445–1446.
70. Bordbar S, Bigi MA, Aslani A, Rahimi E, Ahmadi N. Effect of endurance and strength exercise on release of brain natriuretic peptide. *J Cardiovasc Dis Res* 2012;3:22–25.
71. Bekos C, Zimmermann M, Unger L, et al. Non-professional marathon running: RAGE axis and ST2 family changes in relation to open-window effect, inflammation and renal function. *Sci Rep* 2016;6:32315.